Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study.
von Verschuer U, Schnell R, Tessen HW, Eggert J, Binninger A, Spring L, Jänicke M, Marschner N; TLK-Group (Tumour Registry Lung Cancer). von Verschuer U, et al. Among authors: marschner n. Lung Cancer. 2017 Oct;112:216-224. doi: 10.1016/j.lungcan.2017.07.031. Epub 2017 Sep 12. Lung Cancer. 2017. PMID: 28916198 Free article.
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.
Welt A, Wiesweg M, Theurer S, Abenhardt W, Groschek M, Müller L, Schröder J, Tewes M, Chiabudini M, Potthoff K, Bankfalvi A, Marschner N, Schuler M, Breitenbücher F. Welt A, et al. Among authors: marschner n. Cancer Med. 2020 Jul;9(13):4527-4539. doi: 10.1002/cam4.3092. Epub 2020 Apr 30. Cancer Med. 2020. PMID: 32352244 Free PMC article. Clinical Trial.
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. von Minckwitz G, et al. Among authors: marschner n. Lancet Oncol. 2014 Oct;15(11):1269-78. doi: 10.1016/S1470-2045(14)70439-5. Epub 2014 Sep 28. Lancet Oncol. 2014. PMID: 25273342 Clinical Trial.
Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN).
Knauf W, Abenhardt W, Aldaoud A, Nusch A, Grugel R, Münz M, Hartmann H, Marschner N; TLN Study Group. Knauf W, et al. Among authors: marschner n. Oncol Res Treat. 2014;37(11):635-6, 638-44. doi: 10.1159/000368315. Epub 2014 Oct 17. Oncol Res Treat. 2014. PMID: 25486127 Free article.
Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
Welt A, Marschner N, Lerchenmueller C, Decker T, Steffens CC, Koehler A, Depenbusch R, Busies S, Hegewisch-Becker S. Welt A, et al. Among authors: marschner n. Breast Cancer Res Treat. 2016 Feb;156(1):97-107. doi: 10.1007/s10549-016-3727-x. Epub 2016 Feb 29. Breast Cancer Res Treat. 2016. PMID: 26927446 Free PMC article. Clinical Trial.
Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study.
Fietz T, Zahn MO, Köhler A, Engel E, Frank M, Kruggel L, Jänicke M, Marschner N; TMK-Group (Tumour Registry Breast Cancer). Fietz T, et al. Among authors: marschner n. Breast Cancer Res Treat. 2018 Jan;167(2):567-578. doi: 10.1007/s10549-017-4534-8. Epub 2017 Oct 13. Breast Cancer Res Treat. 2018. PMID: 29030786 Free PMC article.
116 results